1-cyclohexyl-3,3-dimethyl-1-oxo-2-butanaminium chloride | 524950-22-9

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 1-cyclohexyl-3,3-dimethyl-1-oxo-2-butanaminium chloride
• 英文别名: (1-Cyclohexyl-3,3-dimethyl-1-oxobutan-2-yl)azanium;chloride
• CAS: 524950-22-9
• 化学式: C₁₂H₂₃NO*ClH
• 分子量: 233.782
• InChiKey: AHBLWCWWXZJIIR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.93
• 重原子数：
  15
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.92
• 拓扑面积：
  43.1
• 氢给体数：
  2
• 氢受体数：
  2

文献信息

• Novel inhibitors of glutaminyl cyclase
  申请人：Schilling Stephan

  公开号：US20050215573A1

  公开（公告）日：2005-09-29

  The present invention relates to novel inhibitors of glutaminyl cyclase and combinations thereof for the treatment of neuronal disorders, especially Alzheimer's disease, Down Syndrome, Parkinson disease, Chorea Huntington, pathogenic psychotic conditions, schizophrenia, impaired food intake, sleep-wakefulness, impaired homeostatic regulation of energy metabolism, impaired autonomic function, impaired hormonal balance, impaired regulation, body fluids, hypertension, fever, sleep dysregulation, anorexia, anxiety related disorders including depression, seizures including epilepsy, drug withdrawal and alcoholism, neurodegenerative disorders including cognitive dysfunction and dementia.

  本发明涉及新型谷氨酰环化酶抑制剂及其组合物，用于治疗神经系统疾病，特别是阿尔茨海默病、唐氏综合征、帕金森病、亨廷顿舞蹈症、致病性精神病症、精神分裂症、食欲受损、睡眠-觉醒、体内能量代谢的失衡、自主神经功能受损、激素平衡受损、调节失调、体液平衡、高血压、发热、睡眠失调、厌食症、焦虑相关疾病包括抑郁症、癫痫发作包括癫痫、药物戒断和酗酒、神经退行性疾病包括认知功能障碍和痴呆症。
• Inhibitors of glutaminyl cyclase
  申请人：——

  公开号：US20040224875A1

  公开（公告）日：2004-11-11

  The present invention relates to compounds that act as inhibitors of QC including those represented by the general formulae 1 to 9: 1 and combinations thereof for the treatment of neuronal disorders, especially Alzheimer's disease, Down Syndrome, Parkinson disease, Corea Huntington, pathogenic psychotic conditions, schizophrenia, impaired food intake, sleep-wakefulness, impaired homeostatic regulation of energy metabolism, impaired autonomic function, impaired hormonal balance, impaired regulation, body fluids, hypertension, fever, sleep dysregulation, anorexia, anxiety related disorders including depression, seizures including epilepsy, drug withdrawal and alcoholism, neurodegenerative disorders including cognitive dysfunction and dementia.

  本发明涉及一种作为QC抑制剂的化合物，包括由通式1至9表示的化合物及其组合物，用于治疗神经系统疾病，特别是阿尔茨海默病、唐氏综合症、帕金森病、亨廷顿舞蹈症、病理性精神病症、精神分裂症、食欲不振、睡眠-清醒状态、能量代谢的失调、自主神经功能障碍、激素平衡失调、体液调节失调、高血压、发热、睡眠失调、厌食症、焦虑相关障碍包括抑郁症、癫痫包括药物戒断和酗酒，神经退行性疾病包括认知功能障碍和痴呆症。
• Substituted amino ketone compounds
  申请人：Demuth Hans-Ulrich

  公开号：US20050014946A1

  公开（公告）日：2005-01-20

  The present invention relates to compounds of the general formula I B—(CH—R 1 ) n —C(═X 2 )-D   (I) and pharmaceutically acceptable salts thereof including stereoisomers, to the use of the compounds for the treatment of impaired glucose tolerance, glucosuria, hyperlipidaemia, metabolic acidosis, diabetes mellitus, diabetic neuropathy and nephropathy and of sequelae caused by diabetes mellitus in mammals.

  本发明涉及一般公式IB - （CH-R1）n-C（═X2）-D（I）及其药学上可接受的盐，包括立体异构体，用于治疗哺乳动物中的糖耐受障碍，葡萄糖尿病，高脂血症，代谢性酸中毒，糖尿病神经病和肾病以及由糖尿病引起的后遗症。
• Secondary binding site of dipeptidyl peptidase IV (DPIV)
  申请人：Kuhn-Wache Kerstin

  公开号：US20050176622A1

  公开（公告）日：2005-08-11

  The present application relates to the secondary binding site of dipeptidyl peptidase IV, its relationship amongst substrates and to the modulation of substrate specificity of dipeptidyl peptidase IV (DP IV, synonym: DPP IV, CD26, EC 3.4.14.5). The application relates further to compounds that bind to the secondary binding site of DP IV and their use to modulate the substrate specificity of DP IV; methods of treatment of various DP IV mediated disorders; and screening methods for the identification of secondary binding sites on DP IV and DP IV-like enzymes.

  本申请涉及二肽基肽酶IV的次级结合位点，其与底物之间的关系以及调节二肽基肽酶IV（DP IV，同义词：DPP IV，CD26，EC 3.4.14.5）底物特异性的方法。该申请还涉及结合到DP IV的次级结合位点的化合物及其用于调节DP IV底物特异性的应用；各种DP IV介导的疾病的治疗方法；以及用于识别DP IV和DP IV-like酶的次级结合位点的筛选方法。
• Secondary binding site of dipeptidyl peptidase IV (DP IV)
  申请人：Kuhn-Wache Kerstin

  公开号：US20060234940A1

  公开（公告）日：2006-10-19

  The present application relates to the secondary binding site of dipeptidyl peptidase IV, its relationship amongst substrates and to the modulation of substrate specificity of dipeptidyl peptidase IV (DP IV, synonym: DPP IV, CD26, EC 3.4.14.5). The application relates further to compounds that bind to the secondary binding site of DP IV and their use to modulate the substrate specificity of DP IV; methods of treatment of various DP IV mediated disorders; and screening methods for the identification of secondary binding sites on DP IV and DP IV-like enzymes.

  本申请涉及二肽基肽酶IV的次级结合位点，其在底物中的关系以及对二肽基肽酶IV（DP IV，同义词：DPP IV，CD26，EC 3.4.14.5）底物特异性的调节。该申请还涉及结合到DP IV次级结合位点的化合物及其用于调节DP IV底物特异性的使用方法；治疗各种DP IV介导的疾病的方法；以及用于鉴定DP IV和DP IV类酶次级结合位点的筛选方法。